healthsim-trialsim

To generate synthetic clinical trial data for SDTM domains, you can use a natural-language prompt to simulate Phase I–III trials across therapeutic areas like oncology, creating canonical JSON datasets with realistic epidemiology for domains such as DM, AE, and LB.

Yes, you can simulate Phase 3 oncology trial datasets with complete SDTM mappings. The generation process supports phase-appropriate endpoints and produces regulatory-ready outputs suitable for SDTM and ADaM formats across oncology, cardiovascular, CNS, and CGT trials.

The best way to create regulatory-ready synthetic data for clinical trial validation is to generate SDTM-compliant datasets with realistic study design patterns. This approach produces canonical JSON outputs with domain links and provenance suitable for API testing and regulatory QA.

Supported SDTM domains when generating synthetic clinical trial datasets include DM, AE, CM, EX, LB, VS, MH, and DS. These domains are generated with realistic epidemiology and study design patterns to ensure comprehensive trial simulation.

Yes, synthetic clinical trial data generation works for Cell and Gene Therapy (CGT) studies. The generation process supports end-to-end trial scenarios across CGT, oncology, cardiovascular, and CNS therapeutic areas from Phase 1 through Phase 3.